Biologics 2023;17:161–166 doi: 10.2147/BTT.S434318
Siderius, et al. found that secukinumab was associated with low spinal radiographic progression. Furthermore, bone-related outcomes and BTMs related to collagen resorption (sCTX, PINP) remained constant during the 2-year period, whereas the BTM related to mineralisation (BALP) decreased significantly.
The authors explored the effect of 2 years of secukinumab treatment on bone metabolism in patients with radiographic axSpA (r-axSpA). Secukinumab was administered as a subcutaneous injection (150 mg) every 28 days; the frequency was raised to every 21 or 14 days in case of an inadequate clinical response. Larger patient cohorts are required to draw more detailed conclusions on BTM levels in r-axSpA patients, especially concerning dose and gender dependence. Identification of changes in bone formation and loss is crucial for future treatment and monitoring of axSpA.